Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness.

Boileau M, Shirinian M, Gayden T, Harutyunyan AS, Chen CCL, Mikael LG, Duncan HM, Neumann AL, Arreba-Tutusaus P, De Jay N, Zeinieh M, Rossokhata K, Zhang Y, Nikbakht H, Mouawad C, Massoud R, Frey F, Nasr R, El Cheikh J, El Sabban M, Kleinman CL, Mahfouz R, Minden MD, Jabado N, Bazarbachi A, Eppert K.

Nat Commun. 2019 Jun 28;10(1):2891. doi: 10.1038/s41467-019-10705-z.

2.

The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids.

Seneviratne AK, Xu M, Aristizabal Henao JJ, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD.

Cell Stem Cell. 2019 Jun 6;24(6):1007. doi: 10.1016/j.stem.2019.04.020. No abstract available.

PMID:
31173706
3.

Anti-leukemia effect of vitamin K3 is mediated through mitochondrial complexes I and II.

Ibrahim M, Mendis N, Roma A, Jayanth P, Minden MD, Spagnuolo PA.

Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1620940. [Epub ahead of print] No abstract available.

PMID:
31164029
4.

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M.

Cancer Cell. 2019 May 13;35(5):721-737.e9. doi: 10.1016/j.ccell.2019.03.014. Epub 2019 May 2.

PMID:
31056398
5.

DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.

Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, Hermanns T, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U.

J Clin Invest. 2019 Apr 1;129(4):1801. doi: 10.1172/JCI128527. Epub 2019 Apr 1. No abstract available.

6.

The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids.

Seneviratne AK, Xu M, Henao JJA, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD.

Cell Stem Cell. 2019 Apr 4;24(4):621-636.e16. doi: 10.1016/j.stem.2019.02.020. Epub 2019 Mar 28. Erratum in: Cell Stem Cell. 2019 Jun 6;24(6):1007.

PMID:
30930145
7.

A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency.

Kaufmann KB, Garcia-Prat L, Liu Q, Ng SWK, Takayanagi SI, Mitchell A, Wienholds E, van Galen P, Cumbaa CA, Tsay MJ, Pastrello C, Wagenblast E, Krivdova G, Minden MD, Lechman ER, Zandi S, Jurisica I, Wang JCY, Xie SZ, Dick JE.

Blood. 2019 May 16;133(20):2198-2211. doi: 10.1182/blood-2018-10-881441. Epub 2019 Feb 22.

PMID:
30796022
8.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG.

Nat Genet. 2019 Feb;51(2):296-307. doi: 10.1038/s41588-018-0315-5. Epub 2019 Jan 14.

PMID:
30643249
9.

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.

Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD.

Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.

10.

Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.

Khoury H, He R, Schimmer A, Beadle JR, Hostetler KY, Minden MD.

Chemotherapy. 2018;63(4):225-237. doi: 10.1159/000491705. Epub 2018 Oct 29.

PMID:
30372692
11.

DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.

Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, Hermanns T, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U.

J Clin Invest. 2019 Jan 2;129(1):223-229. doi: 10.1172/JCI121303. Epub 2018 Dec 3. Erratum in: J Clin Invest. 2019 Apr 1;129(4):1801.

12.

Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression.

Luciani GM, Xie L, Dilworth D, Tierens A, Moskovitz Y, Murison A, Szewczyk MM, Mitchell A, Lupien M, Shlush L, Dick JE, Arrowsmith CH, Barsyte-Lovejoy D, Minden MD.

Exp Hematol. 2019 Jan;69:27-36. doi: 10.1016/j.exphem.2018.10.006. Epub 2018 Oct 22.

PMID:
30352278
13.

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.

McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469.

14.

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.

Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L, Dombret H.

Leukemia. 2018 Dec;32(12):2546-2557. doi: 10.1038/s41375-018-0257-z. Epub 2018 Oct 1.

15.

Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms.

Kennedy JA, Medeiros JJF, Dobson SM, Arruda A, Sukhai MA, Stockley T, Tierens A, Minden MD, Kamel-Reid S, Dick JE, Gupta V.

Blood. 2018 Nov 15;132(20):2201-2205. doi: 10.1182/blood-2018-04-845065. Epub 2018 Sep 24. No abstract available.

PMID:
30249785
16.

Acute promyelocytic leukemia in the intensive care unit: A retrospective analysis.

Ferreyro BL, Munshi L, Detsky ME, Minden MD, Cheung A, Burry L, Lee C.

Leuk Res. 2018 Oct;73:41-43. doi: 10.1016/j.leukres.2018.08.004. Epub 2018 Aug 31. No abstract available.

PMID:
30216937
17.

Prediction of acute myeloid leukaemia risk in healthy individuals.

Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, Barda N, Zuzarte PC, Heisler L, Sundaravadanam Y, Luben R, Hayat S, Wang TT, Zhao Z, Cirlan I, Pugh TJ, Soave D, Ng K, Latimer C, Hardy C, Raine K, Jones D, Hoult D, Britten A, McPherson JD, Johansson M, Mbabaali F, Eagles J, Miller JK, Pasternack D, Timms L, Krzyzanowski P, Awadalla P, Costa R, Segal E, Bratman SV, Beer P, Behjati S, Martincorena I, Wang JCY, Bowles KM, Quirós JR, Karakatsani A, La Vecchia C, Trichopoulou A, Salamanca-Fernández E, Huerta JM, Barricarte A, Travis RC, Tumino R, Masala G, Boeing H, Panico S, Kaaks R, Krämer A, Sieri S, Riboli E, Vineis P, Foll M, McKay J, Polidoro S, Sala N, Khaw KT, Vermeulen R, Campbell PJ, Papaemmanuil E, Minden MD, Tanay A, Balicer RD, Wareham NJ, Gerstung M, Dick JE, Brennan P, Vassiliou GS, Shlush LI.

Nature. 2018 Jul;559(7714):400-404. doi: 10.1038/s41586-018-0317-6. Epub 2018 Jul 9.

18.

CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice.

Williams BA, Wang XH, Leyton JV, Maghera S, Deif B, Reilly RM, Minden MD, Keating A.

Haematologica. 2018 Oct;103(10):1720-1729. doi: 10.3324/haematol.2017.187385. Epub 2018 Jul 5.

19.

Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.

Laverdière I, Boileau M, Neumann AL, Frison H, Mitchell A, Ng SWK, Wang JCY, Minden MD, Eppert K.

Blood Cancer J. 2018 Jun 6;8(6):52. doi: 10.1038/s41408-018-0087-2.

PMID:
29921955
20.

Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.

Barghout SH, Patel PS, Wang X, Xu GW, Kavanagh S, Halgas O, Zarabi SF, Gronda M, Hurren R, Jeyaraju DV, MacLean N, Brennan S, Hyer ML, Berger A, Traore T, Milhollen M, Smith AC, Minden MD, Pai EF, Hakem R, Schimmer AD.

Leukemia. 2019 Jan;33(1):37-51. doi: 10.1038/s41375-018-0167-0. Epub 2018 Jun 8.

PMID:
29884901
21.

Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy.

Chen B, Lee JB, Kang H, Minden MD, Zhang L.

J Exp Clin Cancer Res. 2018 Apr 24;37(1):88. doi: 10.1186/s13046-018-0756-9.

22.

AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.

Kavanagh S, Heath E, Hurren R, Gronda M, Barghout SH, Liyanage SU, Siriwardena TP, Claudio J, Zhang T, Sukhai M, Stockley TL, Kamel-Reid S, Rostom A, Lutynski A, Khalaf D, Rydlewski A, Chan SM, Gupta V, Maze D, Sibai H, Schuh AC, Yee K, Minden MD, Schimmer AD.

Leuk Res. 2018 May;68:22-28. doi: 10.1016/j.leukres.2018.02.012. Epub 2018 Feb 20.

PMID:
29518628
23.

SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML.

Dzneladze I, Woolley JF, Rossell C, Han Y, Rashid A, Jain M, Reimand J, Minden MD, Salmena L.

PLoS One. 2018 Feb 7;13(2):e0191510. doi: 10.1371/journal.pone.0191510. eCollection 2018. Erratum in: PLoS One. 2018 Mar 29;13(3):e0195417.

24.

A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.

Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD, Hirano N.

Nat Med. 2018 Mar;24(3):352-359. doi: 10.1038/nm.4478. Epub 2018 Feb 5.

25.

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.

Spiegel JY, McNamara C, Kennedy JA, Panzarella T, Arruda A, Stockley T, Sukhai M, Thomas M, Bartoszko J, Ho J, Siddiq N, Maze D, Schimmer A, Schuh A, Sibai H, Yee K, Claudio J, Devlin R, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2017 Sep 8;1(20):1729-1738. doi: 10.1182/bloodadvances.2017009530. eCollection 2017 Sep 12.

26.

Stability of sodium bicarbonate injection 8.4% in syringes over a six-week period in refrigerated temperature.

Seki JT, Wang TQ, Yip PM, Mazzulli T, Minden MD.

J Oncol Pharm Pract. 2018 Apr;24(3):198-200. doi: 10.1177/1078155217694493. Epub 2017 Feb 20.

PMID:
29284355
27.

The utility and safety of flexible bronchoscopy in critically ill acute leukemia patients: a retrospective cohort study.

Deotare U, Merman E, Pincus D, Kraguljac AP, Croucher D, Kumar V, Ibrahimova N, Minden MD, Lee C, Mehta S.

Can J Anaesth. 2018 Mar;65(3):272-279. doi: 10.1007/s12630-017-1041-7. Epub 2017 Dec 18.

PMID:
29256064
28.

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H.

BMC Cancer. 2017 Dec 14;17(1):852. doi: 10.1186/s12885-017-3803-6.

29.

Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.

Lee J, Minden MD, Chen WC, Streck E, Chen B, Kang H, Arruda A, Ly D, Der SD, Kang S, Achita P, D'Souza C, Li Y, Childs RW, Dick JE, Zhang L.

Clin Cancer Res. 2018 Jan 15;24(2):370-382. doi: 10.1158/1078-0432.CCR-17-2228. Epub 2017 Oct 26.

30.

Evolution of AF6-RAS association and its implications in mixed-lineage leukemia.

Smith MJ, Ottoni E, Ishiyama N, Goudreault M, Haman A, Meyer C, Tucholska M, Gasmi-Seabrook G, Menezes S, Laister RC, Minden MD, Marschalek R, Gingras AC, Hoang T, Ikura M.

Nat Commun. 2017 Oct 23;8(1):1099. doi: 10.1038/s41467-017-01326-5.

31.

Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients.

Bhimji A, Bhaskaran A, Singer LG, Kumar D, Humar A, Pavan R, Lipton J, Kuruvilla J, Schuh A, Yee K, Minden MD, Schimmer A, Rotstein C, Keshavjee S, Mazzulli T, Husain S.

Clin Microbiol Infect. 2018 Jun;24(6):640-645. doi: 10.1016/j.cmi.2017.09.018. Epub 2017 Sep 29.

32.

Estrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia.

Rota SG, Roma A, Dude I, Ma C, Stevens R, MacEachern J, Graczyk J, Espiritu SMG, Rao PN, Minden MD, Kreinin E, Hess DA, Doxey AC, Spagnuolo PA.

Mol Cancer Ther. 2017 Nov;16(11):2618-2626. doi: 10.1158/1535-7163.MCT-17-0292. Epub 2017 Aug 23.

33.

Tracing the origins of relapse in acute myeloid leukaemia to stem cells.

Shlush LI, Mitchell A, Heisler L, Abelson S, Ng SWK, Trotman-Grant A, Medeiros JJF, Rao-Bhatia A, Jaciw-Zurakowsky I, Marke R, McLeod JL, Doedens M, Bader G, Voisin V, Xu C, McPherson JD, Hudson TJ, Wang JCY, Minden MD, Dick JE.

Nature. 2017 Jul 6;547(7661):104-108. doi: 10.1038/nature22993. Epub 2017 Jun 28.

PMID:
28658204
34.

Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.

Farshchi Zarabi S, Chan S, Gupta V, Khalaf D, Lutynski A, Minden MD, Rostom A, Rydlewski A, Schuh AC, Sibai H, Yee KWL, Schimmer AD.

Leuk Lymphoma. 2018 Jan;59(1):237-240. doi: 10.1080/10428194.2017.1323273. Epub 2017 Jun 9. No abstract available.

PMID:
28595467
35.

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.

Xie LH, Biondo M, Busfield SJ, Arruda A, Yang X, Vairo G, Minden MD.

Blood Cancer J. 2017 Jun 2;7(6):e567. doi: 10.1038/bcj.2017.52.

36.

HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway.

Yamashita Y, Anczurowski M, Nakatsugawa M, Tanaka M, Kagoya Y, Sinha A, Chamoto K, Ochi T, Guo T, Saso K, Butler MO, Minden MD, Kislinger T, Hirano N.

Nat Commun. 2017 May 10;8:15244. doi: 10.1038/ncomms15244.

37.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

38.

Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.

Guo RJ, Atenafu EG, Schimmer AD, Minden MD, Chang H.

Int J Lab Hematol. 2017 Aug;39(4):429-437. doi: 10.1111/ijlh.12649. Epub 2017 Mar 20.

PMID:
28318150
39.

Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.

Liyanage SU, Hurren R, Voisin V, Bridon G, Wang X, Xu C, MacLean N, Siriwardena TP, Gronda M, Yehudai D, Sriskanthadevan S, Avizonis D, Shamas-Din A, Minden MD, Bader GD, Laposa R, Schimmer AD.

Blood. 2017 May 11;129(19):2657-2666. doi: 10.1182/blood-2016-10-741207. Epub 2017 Mar 10.

40.

SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.

Zipin-Roitman A, Aqaqe N, Yassin M, Biechonski S, Amar M, van Delft MF, Gan OI, McDermott SP, Buzina A, Ketela T, Shlush L, Xie S, Voisin V, Moffat J, Minden MD, Dick JE, Milyavsky M.

Oncotarget. 2017 Mar 7;8(10):16712-16727. doi: 10.18632/oncotarget.15147.

41.

Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia.

Tong J, Helmy M, Cavalli FM, Jin L, St-Germain J, Karisch R, Taylor P, Minden MD, Taylor MD, Neel BG, Bader GD, Moran MF.

Proteomics. 2017 Mar;17(6). doi: 10.1002/pmic.201600361.

42.

Biological and clinical consequences of NPM1 mutations in AML.

Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD.

Leukemia. 2017 Apr;31(4):798-807. doi: 10.1038/leu.2017.30. Epub 2017 Jan 23. Review.

PMID:
28111462
43.

5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.

Ahn JS, Kim HJ, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Park HJ, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Michael S, Minden MD, Kim DD.

Oncotarget. 2017 Jan 31;8(5):8305-8314. doi: 10.18632/oncotarget.14171.

44.

Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.

Ren Z, Aerts JL, Vandenplas H, Wang JA, Gorbenko O, Chen JP, Giron P, Heirman C, Goyvaerts C, Zacksenhaus E, Minden MD, Stambolic V, Breckpot K, De Grève J.

Cell Death Dis. 2016 Dec 22;7(12):e2560. doi: 10.1038/cddis.2016.430.

45.

Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML.

Huang J, Liu Y, Au BC, Barber DL, Arruda A, Schambach A, Rothe M, Minden MD, Paige CJ, Medin JA.

Mol Ther Methods Clin Dev. 2016 Dec 7;3:16074. eCollection 2016.

46.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

PMID:
27926740
47.

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG.

J Clin Oncol. 2017 Feb;35(4):394-401. doi: 10.1200/JCO.2016.69.0073. Epub 2016 Nov 21.

48.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.

Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA Jr, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG.

Nat Commun. 2016 Nov 8;7:13331. doi: 10.1038/ncomms13331.

49.

Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.

Rotin LE, MacLean N, Aman A, Gronda M, Lin FH, Hurren R, Wang X, Wrana JL, Datti A, Al-Awar R, Minden MD, Schimmer AD.

Haematologica. 2016 Nov;101(11):e449-e453. Epub 2016 Sep 1. No abstract available.

50.

Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.

Seymour JF, Döhner H, Minden MD, Stone R, Gambini D, Dougherty D, Beach CL, Weaver J, Dombret H.

Leuk Lymphoma. 2017 Jun;58(6):1412-1423. doi: 10.1080/10428194.2016.1243680. Epub 2016 Oct 14.

PMID:
27739920

Supplemental Content

Loading ...
Support Center